What Delpral Treats: Main Uses and Benefits

Delpral is a medication that plays a role in managing symptomatic relief across therapeutic domains marked by heightened physiological activity and tension. It offers supportive therapeutic benefit in clinical settings where pronounced symptoms interfere with a patient's stability and comfort.

The therapeutic indications for the active substance Tiapride include controlling severe psychomotor agitation and aggressiveness, managing involuntary motor movements (dyskinesias), and providing support during acute Alcohol Withdrawal Syndrome (AWS).

Symptom Domains and Benefits

The medication is commonly used across conditions presenting with symptoms associated with acute or episodic changes where supportive relief is needed. It helps address symptom clusters that create noticeable functional strain, such as tremor and excitement in AWS, or the severe restlessness and aggressiveness seen in geriatric patients.

“Delpral supports patients during difficult episodes by easing distress and contributing to emotional stability.”

By easing the severity of these abnormal motor behaviors and emotional outbursts, Delpral assists with maintaining functional stability when symptoms interfere with daily functioning. It is relevant when short-term symptomatic assistance is needed to help patients cope more steadily.

Regulatory References

1. Dutch Medicines Evaluation Board (CBG-MEB)

Who can and cannot use Delpral?

Delpral is officially authorized for use in the adult population (18 years and above). Regulatory labeling defines strict population-based exclusions and mandatory restrictions for its use.

Absolute Contraindications

Use is strictly prohibited in patients with the following conditions or co-treatment:

• Known hypersensitivity to tiapride hydrochloride.
• Prolactin-dependent tumours (e.g., pituitary prolactinoma, breast cancer).
• Phaeochromocytoma.
• Concomitant treatment with Levodopa (or other dopamine agonists).

Population Restrictions

The medicine is not recommended for children and adolescents under 18 years of age because safety and efficacy have not been established.

Use requires extreme caution and monitoring in specific populations:

• Renal Impairment necessitates dosage reduction.
• Elderly patients must be monitored closely due to an increased risk of adverse effects.
• Patients with a history of epilepsy or risk factors for QT-interval prolongation require special consideration.
• Parkinson’s disease patients should generally avoid this medicine.
• Pregnancy and lactation status define non-recommended use, with breastfeeding advised to be discontinued.

Officially Documented Interactions

Interactions with Delpral (Tiapride) are primarily documented by regulatory bodies based on two significant pharmacodynamic (PD) risk categories: antagonism at dopamine receptors and synergistic risk for severe cardiac events.

Formal Contraindications

Co-administration is formally contraindicated with specific agents due to the severe risk of ventricular arrhythmias, notably torsades de pointes. This includes certain anti-infective agents (e.g., halofantrine, moxifloxacin, IV erythromycin, IV spiramycin, pentamidine, IV vincamine) and other non-antiarrhythmic medicines (e.g., bepridil, cisapride, hydroxyzine). Furthermore, non-Parkinsonian dopaminergic agonists (e.g., cabergoline, quinagolide) are contraindicated due to reciprocal antagonism of effects.

Pharmacodynamic & Exposure Risks

• CNS Depressants: Pharmacodynamic synergy occurs with all Central Nervous System depressants (including opioids, benzodiazepines, sedative antidepressants, and hypnotics), leading to an enhancement of the sedative effect and potential alteration of vigilance.

• Levodopa/Parkinsonian Agonists: Reciprocal antagonism of effects occurs with Levodopa and other dopaminergic agonists used in Parkinson's disease, reducing the efficacy of both agents.

• Cardiac Risk Modifiers: Caution is required with agents that increase the risk of torsades de pointes by causing bradycardia (e.g., beta-blockers, cardiac glycosides) or potassium depletion (e.g., potassium-lowering diuretics, stimulant laxatives). The regulatory label mandates avoidance of alcohol due to documented potentiation of sedation.

• Population-Specific Note: Interaction risks may be increased in the elderly due to heightened sedation potential and in patients with renal impairment due to reduced drug clearance.

Delpral functions as a monoamine oxidase inhibitor (MAOI), specifically targeting and covalently modifying the enzyme Monoamine Oxidase A (MAO-A), a flavin-adenine dinucleotide (FAD)-containing enzyme. The drug irreversibly binds to the active site of MAO-A, forming a stable, non-functional complex. This inhibitory interaction prevents the oxidative deamination and subsequent catabolism of endogenous monoamine neurotransmitters, including norepinephrine, serotonin, and dopamine, within neuronal synaptic clefts and cytoplasm. The resulting intracellular pathway consequence is a substantial and sustained increase in the concentration of these specific monoamines within presynaptic nerve terminals. The downstream cascade involves an enhancement of neurotransmitter release and prolonged receptor binding activity at the postsynaptic membrane. This molecular action ultimately leads to system-level physiological consequences characterized by an overall augmented monoaminergic neurotransmission in central nervous system circuits.

How to Use Delpral (Tiapride)

Delpral is administered through two primary approaches: oral delivery, used for maintenance and ongoing management, and parenteral delivery (Intramuscular or Intravenous injection) for acute stabilization. The total daily dose is typically divided into two or three separate administrations to maintain consistent levels of the active substance, Tiapride.

Dosing and Frequency Patterns

Dosing is tailored to the specific context of use. For general adult maintenance, the dose commonly falls between 100 mg and 300 mg daily. Higher doses are utilized for short-term, acute symptom control; for example, managing severe symptoms associated with alcohol withdrawal may involve daily doses from 400 mg to 1200 mg, with a maximum threshold of 1800 mg if necessary.

Population-Specific Use

Dose adjustments are required for certain populations. Due to its renal clearance, Delpral dosing must be significantly reduced in patients with impaired kidney function. Furthermore, a reduced starting dose is utilized for older adults due to increased sensitivity. For specific therapeutic uses, Tiapride is not recommended for children below 18 years of age in some regions, pending established safety data.

Research Evidence / Overview of Studies for Delpral

Evidence for Use in Managing Severe Psychomotor Agitation

Research has explored the evaluation of Delpral in specific studies addressing sudden and severe psychomotor agitation and aggressiveness, particularly in older adult patients with cognitive impairment. The clinical evaluation used short-term Randomized Controlled Trials (RCTs) and observational studies. Researchers monitored outcomes capturing phases of heightened symptom activity, reporting patterns related to how measured aggression and restlessness scores evolved. However, the evidence is largely descriptive of short-term relief (typically 7 to 28 days), and long-term effects are not fully established.

Evidence for Use in Acute Alcohol Withdrawal Syndrome

Delpral was evaluated in clinical trials focusing on the study of symptom patterns during the acute Alcohol Withdrawal Syndrome (AWS), a condition marked by functional imbalance. Research examined outcomes related to systemic or physiological strain, such as withdrawal severity (e.g., CIWA-Ar) and complications. Studies also explored the role of tiapride in research settings focused on abstinence maintenance over up to six months. Modest sample sizes and heterogeneity of evidence characterize many of the acute-phase trials.

Evidence for Use in Dyskinesia and Involuntary Movements

Delpral was studied for its evaluation in studies addressing different types of involuntary motor movements (dyskinesia), including tardive dyskinesia and chorea. These research efforts primarily consisted of older, smaller-scale clinical trials. Studies monitored outcomes related to functional imbalance, quantifying the change in motor symptom severity using established rating scales. The evidence for this indication is limited, lacking a volume of recent, large-scale RCTs, and follow-up durations were typically brief (a few months).

Research Gaps and Uncertainties Remain

The research highlights what is known and what is still uncertain about Delpral. Key limitations include the fact that the evidence quality varies across studies, with many of the key trials being older or having modest sample sizes. For all indications, the evidence is largely descriptive of short-term symptom patterns, and there is limited information for long-term outcomes that would provide a comprehensive view of sustained stability.

Key Studies & References

1. Measuring the efficacy of psychopharmacological treatment of psychomotoric restlessness in dementia: clinical evaluation of tiapride
2. Tiaprid Pharmagen 100 mg tablets: Public Assessment Report (Regulatory Document)

Common questions about Delpral (FAQ)

Q: Is Delpral an MAOI or a Dopamine Antagonist?

A: According to official product information, Delpral’s active ingredient, tiapride, is classified as an Atypical Antipsychotic and a Dopamine Antagonist. This means its action involves selectively blocking certain dopamine receptors (D2 and D3) in the brain.

Q: Is Delpral a type of blood pressure medication?

A: No, Delpral is not indicated for treating high blood pressure. It is classified as an Atypical Antipsychotic/Neuroleptic and is used specifically for managing Central Nervous System disturbances, such as severe agitation and dyskinesia (involuntary movements).

Q: How quickly should I expect Delpral to start working after I begin treatment?

A: Regulatory documents indicate that the active substance in Delpral is rapidly absorbed by the body, typically reaching its maximum concentration within about one hour after being taken. However, the full therapeutic benefit may require a longer duration of treatment, as the clinical response varies.

Q: Is Delpral a long-term treatment or is it usually for short periods?

A: Some authorized indications, such as severe agitation, are typically managed for short periods. Official information notes that serious reactions, like tardive dyskinesia (involuntary movements), are associated with prolonged treatment, typically lasting longer than three months.

Q: Does Delpral typically cause weight gain or weight loss?

A: Weight changes are not listed as a common side effect. However, official safety data lists hyperprolactinaemia (increased prolactin levels) as an uncommon side effect, and this condition is sometimes associated with weight gain.

Q: Can Delpral affect my kidney function over time?

A: The drug is primarily excreted by the kidneys, which is why dosing is adjusted for existing renal impairment. The label does not specifically state that the drug causes kidney damage in individuals with normal function.

Q: Are there any long-term side effects associated with Delpral use?

A: Yes, regulatory documents highlight the potential for Tardive dyskinesia as a long-term risk. This serious adverse reaction involves involuntary, rhythmic movements and is specifically associated with prolonged treatment, typically after several months.

Q: Does Delpral interact with common supplements like potassium or herbal remedies?

A: Official product information notes caution when Delpral is used alongside any medicine or supplement that can cause potassium depletion in the body. Low potassium levels increase the risk of severe heart rhythm problems (arrhythmias).

Q: What over-the-counter (OTC) pain relievers might interact with Delpral?

A: Regulatory documents list categories of medicines that require caution, including those that are CNS depressants (which can enhance sedation) or those that slow the heart rate (bradycardia).

Q: Can individuals with liver problems use Delpral?

A: The active substance is mainly eliminated by the kidneys and is not significantly metabolized by the liver.

Q: Is there a risk of swelling (angioedema) with Delpral, and what does it look like?

A: Swelling of the face, lips, or throat (angioedema) is not listed as a documented adverse reaction in the official safety profile for tiapride.

Q: Does stopping Delpral suddenly cause any rebound effects or withdrawal symptoms?

A: The product information notes that use in late pregnancy has been linked to potential withdrawal reactions in the newborn. The product information does not explicitly list withdrawal symptoms upon cessation for adult use. However, sudden cessation of neuroleptic medicines is generally discouraged.

Q: What kind of monitoring (blood tests, check-ups) is needed while taking Delpral?

A: Official safety documents indicate that monitoring is necessary during treatment. This may include an ECG (electrocardiogram) to check the QT interval for heart rhythm stability. Monitoring for high prolactin levels may also be advised.

Q: Is it safe to drive or operate machinery when taking Delpral?

A: Because Delpral can cause dizziness and drowsiness (somnolence), the regulatory label advises patients that their ability to drive or operate machinery may be impaired.

Q: What are the signs of an allergic reaction to Delpral?

A: Known hypersensitivity to the active ingredient is a formal contraindication. While specific signs are not fully detailed in the label, any signs of a severe allergic reaction (such as swelling or difficulty breathing) should be reported promptly.

Q: Can Delpral cause problems with concentration or memory?

A: Common side effects include drowsiness (somnolence) and dizziness. These effects may indirectly affect general alertness and concentration.

Q: Is Delpral known to cause any issues with sexual function?

A: The uncommon side effect of hyperprolactinaemia (increased prolactin in the blood) is noted in the label as potentially being associated with issues related to sexual function.

Q: How does Delpral influence the body's salt and water balance?

A: The drug's elimination happens primarily through the kidneys and official product information notes caution when Delpral is used alongside potassium-lowering agents. These are factors involved in the body's salt and water balance.

Q: Why do some people experience a change in taste with Delpral?

A: A change in taste sensation (Dysgeusia) is not listed as a common or serious adverse event in the official adverse reaction profile for Delpral.

Q: Can Delpral cause an increased heart rate?

A: Delpral carries a documented risk of QT-interval prolongation and severe ventricular arrhythmias. However, an increased heart rate (tachycardia) is not specifically listed as a common or serious adverse event in the product's safety profile.

Q: What is the difference between Delpral and other ACE inhibitors?

A: Delpral is classified as an Atypical Antipsychotic/Dopamine Antagonist, which places it in a different pharmacological class entirely from ACE inhibitors (a class of medicines typically used for blood pressure and certain heart conditions).

Q: Why is Delpral sometimes combined with a diuretic drug?

A: Official product information notes caution when Delpral is used alongside potassium-lowering diuretics. This is because the combination can lead to a drop in potassium, which significantly increases the risk of serious heart rhythm problems.

Storage and Disposal Requirements for Delpral

The medicine's stability is maintained under specific regulatory conditions, which include requirements for temperature, environmental protection, and handling.

Storage Conditions

Delpral (Tiapride) must be stored at a temperature up to 25°C and must be kept in its original packaging. The product requires protection from direct sunlight, heat, and moisture. To prevent accidental ingestion, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Delpral must be disposed of according to official guidelines. This involves utilizing drug take-back programs or a mail-back envelope program when available. It is explicitly stated that the medicine must not be emptied into drains or wastewater systems. Any remainder of the injectable solution or liquid forms must be immediately discarded and not saved for later use.